SAN ANTONIO -- Researchers at The University of Texas M. D. Anderson Cancer Center have developed two genomic tests to better predict how breast cancer patients will respond to chemotherapy or hormonal therapy.In presentations Dec. 14-15 at the San Antonio Breast Cancer Symposium, the research team reports on a highly sensitive multiple-gene test designed to predict response to chemotherapy, performed before surgery at M.D. Anderson, and a genomic index that gauges 10-year survival for patients who receive post-operative hormonal therapy with the drug tamoxifen. >>> Discuss This Story
